Hamish Ryder

Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives

Michael W. Roe, Adrian Folkes, Philip J. Ashworth et al. · Bioorganic & Medicinal Chemistry Letters · 1999 · 164 citations

Molecular Pharmacology, Medicinal Chemistry, Pharmaceutical Science +12

Characterization of Aclidinium Bromide, a Novel Inhaled Muscarinic Antagonist, with Long Duration of Action and a Favorable Pharmacological Profile

Amadeu Gavaldà, Montserrat Miralpeix, Israel Ramos et al. · Journal of Pharmacology and Experimental Therapeutics · 2009 · 125 citations

Synthesis and Biological Evaluation of 3,4-Diaryloxazolones:  A New Class of Orally Active Cyclooxygenase-2 Inhibitors

Carles Puig, M. Crespo, Núria Godessart et al. · Journal of Medicinal Chemistry · 1999 · 98 citations · Full text

Medicinal Chemistry, Cox-2 Selectivity, Pharmaceutical Science +15

Identifying small-molecule lead compounds: The screening approach to drug discovery

Paul Bevan, Hamish Ryder, Ian Shaw · Trends in biotechnology · 1995 · 83 citations

Medicinal Chemistry, Drug Target, Hit Identification +11

(3<i>R</i>)-<i>N</i>-(1-(<i>tert</i>-Butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1<i>H</i>- 1,4-benzodiazepin-3-yl)-<i>N</i>‘-(3-(methylamino)phenyl)urea (YF476):  A Potent and Orally Active Gastrin/CCK-B Antagonist

Graeme Semple, Hamish Ryder, David P. Rooker et al. · Journal of Medicinal Chemistry · 1997 · 73 citations · Full text

Rat Pancreas, Gastrointestinal Pharmacology, Gastroenterology +17